Recently, ATM and ATR have been selected as potential pharmacological targets in the CONCORDE platform—the first phase Ib randomized, open-label, multi-institution, multi-arm clinical trial seeking to determine the safety profile of several DDR inhibitory agents in combination with fixed-dose radical radiotherapy in locally advanced non-small cell lung carcinomas (LA-NSCLC). This evidence concerns the gene ATM and non-small cell lung carcinoma.